Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My guess? It is a broad market issue. The broad market will rally on a stimulus deal. Risk on. I think it is that simple.
break out!
I have no problem with you posting your trade history. I find it interesting. If you influence anyone to sell, then that creates liquidity. No problem with that at all. I'm long and appreciate the increase in the MA. I like looking at my portfolio and seeing increased SP. Why people knock traders, especially shorts, is beyond me. Price discovery, absent nefarious acts, is just price discovery. That's agnostic.
Moats, my friend. Just no moats in the cannabis space. FDA approval will provide those in this space like MMEDF the necessary protection from crap competitors who drive down margins.
Good call. Volatile stock has volatile price action. News at 11.
No. There are moats, here.
Johns Hopkins’ psilocybin depression study
From my daily Tim Ferris email:
What I’m celebrating —
Johns Hopkins’ psilocybin depression study is the most talked about JAMA Psychiatry article of 2020. Dr. Roland Griffiths from the Center for Psychedelic & Consciousness Research sent me the following: “I am pleased to report that JAMA Psychiatry (@JAMAPsych), often considered to be the most prestigious psychiatry journal in the United States, just released the notice below showing that our psilocybin depression study ranked #1 on their quantitative assessment of attention each scholarly article received in traditional and social media (Altmetric methodology). The relative score of 2416 is substantially greater than the other high impact articles. This is even more impressive given that our study was published in November while other articles were published earlier in the year so had a longer time to get attention.” Click here to see the ranking.
Key Points
Question Is psilocybin-assisted therapy efficacious among patients with major depressive disorder?
Findings In this randomized clinical trial of 24 participants with major depressive disorder, participants who received immediate psilocybin-assisted therapy compared with delayed treatment showed improvement in blinded clinician rater–assessed depression severity and in self-reported secondary outcomes through the 1-month follow-up.
Meaning This randomized clinical trial found that psilocybin-assisted therapy was efficacious in producing large, rapid, and sustained antidepressant effects in patients with major depressive disorder.
Conflict of Interest Disclosures: Dr Davis reported being a board member at Source Research Foundation. Dr Johnson reported receiving grants from Heffter Research Institute outside the submitted work and personal fees as a consultant and/or advisory board member from Beckley Psychedelics Ltd, Entheogen Biomedical Corp, Field Trip Psychedelics Inc, Mind Medicine Inc, and Otsuka Pharmaceutical Development & Commercialization Inc. Dr Griffiths reported being a board member at Heffter Research Institute and receiving grants from Heffter Research Institute outside the submitted work. No other disclosures were reported.
This post has not aged well.
Wonder how The Queen sees it?
That's just brazen.
Beautiful tribute.
Heartbreaking news.
CW didn't miss. I've seen that assertion elsewhere. From the 3Q2019 earnings call transcript:
We had anticipated an update from the FDA before now, but as of today, there is no further guidance. This requires us to readjust our near-term growth expectations. So until such time as the FDA clarifies regulations, we expect our future year-on-year growth rates to continue in the 40% to 50% range, which includes 2019. This revises our 2019 revenue expectations in the range of $95 million to $105 million.
There's been a lot of good news with CW the past few weeks (i.e., CW Lab Sciences, GRAS, Abacas, and now LOC) so there should be plenty to talk about on the conference call tomorrow in the midst of a terrible market and earnings that probably won't be stellar based on the company's own guidance.
A LOC? This is fantastic news.
We also know that CW's record harvest won't go to waste.
Enables Abacus to utilize Charlotte’s Web’s high-quality hemp extract across product portfolio
Provides economies of scale to create in-market cost advantage
This made me laugh.
Cweb gets GRAS certification.
You have bigger ones than moi. I'll reassess after CW's earnings.
Charlotte's Web Takes Steps Towards Scientific Legitimacy
I know Darth was posting about this last week. Solid piece on CW's new R&D initiative.
https://seekingalpha.com/article/4332015-charlottes-web-takes-steps-towards-scientific-legitimacy?utm_medium=email&utm_source=seeking_alpha&mail_subject=cwbhf-charlotte-s-web-takes-steps-towards-scientific-legitimacy&utm_campaign=rta-stock-article&utm_content=link-0
At first they came for Super_Trades
And I did nothing...
And then they came for Darth_Yoda
And I did nothing...
Curious how much of that hemp will actually be harvested and turned into an end product (of any sort).
I've been following all of it. The sector is crowded with turd.
No one has a problem with anyone reversing a position.* Intelligent people do so all the time. It is the way people go about it, however, that can be telling.
*Edit: Or, rather, no one should.
Precisely. "I never liked her anyway."
You've declared on these boards that it works. Why the reversal?
Waiting for the late day reversal.
...or the board is a mess and there is noting to talk about right now. Those are probably more likely reasons for Darth Yoda's absence.
Projections were made in 2018 based on the passage of FDA regs that allowed CW to sell all its products nationally.
This is the same type of of insincere, emotional tripe you posted 6 months ago before you thankfully went away. Do the same again.
In Brands We Trust
https://www.edelman.com/sites/g/files/aatuss191/files/2019-06/2019_edelman_trust_barometer_special_report_in_brands_we_trust.pdf
Transparency is important in the US and some of the biggest markets in the world.
What do you expect the company to say? A PR was put out in August by the CEO expressing his disappointment in the market's reaction to 2Q earnings. While one might debate whether that was prudent, it didn't have a lasting effect on the stock price. What could the company say now that hasn't already been stated in the earnings call? You have to ride this out. Repeating bad news is not a good look.
Searched but couldn't find it. I'll check on PACER later.
Proof that Thanksgiving Eve is one of the biggest drinking days of the year. Get a grip.
You're becoming obvious, oowwwwwooohhhhooooo
That wasn't the tone of your post at all. You took the article at face value, and then alleged that CW engaged in deceptive practices. Your post wasn't anything evenhanded about how this was a PR nightmare for CW. It was disappointing to read from you.
The balm does not advertise CBD content. It advertises the amount of hemp extract. The article specifically states that this is the test:
Over the past three months we worked with Confidence Analytics, a Washington state-licensed cannabis lab and founding partner of our Leafly Certified Labs Program, to test an array of CBD products. We wanted to see which brands delivered what they promised—and which did not.
What's your basis for the following:
I am going to be totally honest with YOU here. I don't think there is going to be any Regulations for a while. The FDA has hinted that a couple of times in the past month. So we are all stuck here for the long run or else, move your money now.
You're analyzing CW's financials with a household finance/small business mentality. Corporate finance is a completely different ballgame. You can't look at spending and debt negatively, especially in an emerging market like cannabis where there is a lot of available market share to gobble up and secure.
Fantastic response. Truth.
whiskey or GTFO
Relevant:
And no, I’m an asshole, not arrogant. Big difference
Do you know how long the product will keep? That would help to know before getting in a debate over inventory.